RANKOR: Direct Drug Prioritization from Bulk and Single-Cell Transcriptomic Signatures
Abstract
BackgroundPrioritizing therapeutics from transcriptomic data remains a key challenge in precision medicine. Signature reversal approaches, most commonly implemented through Gene Set Enrichment Analysis (GSEA), have been widely used to match disease signatures to candidate drugs. However, enrichment-based methods can be sensitive to noise and are restricted to previously profiled compounds MethodsWe developed RANKOR, a machine-learning framework designed to rank candidate drugs directly from transcriptomic signatures. Rather than predicting full expression profiles, RANKOR learns structured latent representations of transcriptional responses alongside chemical structure, enabling prioritization from standardized signatures derived from disease states or treatment perturbations. The framework is applicable to both bulk and single-cell transcriptomic data. ResultsAcross large-scale perturbational datasets, RANKOR achieved consistently lower median ranks than similarity- and distance-based approaches, while showing performance comparable to, and in some settings improved over, GSEA. The model generalized across unseen cell types and retained performance in single-cell settings, where it provided more consistent prioritization than existing approaches, such as ASGARD. RANKOR further enabled prioritization of transcriptionally unseen compounds through chemical-space embedding and achieved substantially reduced computation times. Robustness analyses demonstrated stable performance under moderate noise and degradation under extreme perturbation or gene shuffling. Gene attribution analyses indicated that prioritization decisions are driven by coherent and mechanism-relevant transcriptional programs. ConclusionsRANKOR provides a scalable framework for transcriptomics-guided drug prioritization that can complement and extend existing approaches, such as GSEA. It can also support therapeutic hypothesis generation from bulk and single-cell data while leveraging the generalisability and computational efficiency of machine learning models.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Causal reasoning over knowledge graphs leveraging drug-perturbed and disease-specific transcriptomic signatures for drug discovery
Daniel Domingo‐Fernándéz, Yojana Gadiya, … Viswa Colluru·PLoS Computational BiologyPeer-reviewed·Feb 25, 2022
- Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing
Belinda B. Garana, James H. Joly, … Nicholas Alexander Graham·BMC BioinformaticsPeer-reviewed·May 24, 2023
- Transcriptomic data and biomedical literature synergize in finding pharmacologic gene regulators
Cole A. Deisseroth, Bess Brazelton, … Huda Yahya Zoghbi·bioRxiv·Oct 5, 2026
- Personalizing chemotherapy drug selection using a novel transcriptomic chemogram
Kristi Lin‐Rahardja, Jessica A. Scarborough, Jacob G. Scott·PLoS Computational BiologyPeer-reviewed·Sep 10, 2025
- Differentiable Gene Set Enrichment Analysis for Pathway-Level Supervision in Transcriptomic Learning
Shuaiyu Li, Yang Ruan, … Hiroto Saigo·bioRxiv·Mar 20, 2026
- Integrating single-cell and bulk transcriptomic perturbation resources reveals complementary therapeutic spaces for drug repurposing
Enock Niyonkuru, Umair Khan, … Marina Sirota·bioRxiv·Jul 22, 2026